Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.01%||170.19||0.7%||$968.89m|
|MRK||Merck & Co., Inc.||1.18%||89.53||0.7%||$782.75m|
|LLY||Eli Lilly & Co.||0.15%||302.94||1.1%||$765.74m|
|BMY||Bristol-Myers Squibb Co.||1.59%||74.97||1.0%||$667.48m|
|SIGA||SIGA Technologies, Inc.||2.70%||22.79||0.0%||$421.60m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-3.19%||223.37||8.1%||$270.23m|
|GBT||Global Blood Therapeutics, Inc.||-0.02%||66.59||5.6%||$260.89m|
|HZNP||Horizon Therapeutics Plc||-3.63%||67.12||5.4%||$204.87m|
Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.